Research and Markets: PharmaLeaders: Global Pharmaceutical Market Benchmark Report 2014: Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/297z9b/pharmaleaders) has announced the addition of the "PharmaLeaders: Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies" report to their offering.

Pfizer was the Peer Group Benchmark Leader

According to the authors's proprietary benchmarking analysis, Pfizer was the Global Pharmaceutical Market Benchmark Leader in 2013 with an overall score of 6.22. Pfizer's leadership status was the result of cost-cutting largely the headcount reductions from the divesture of its Animal Health business. This, along with other rationalization measures, contributed to the company's income growth, and helped to drive Pfizer's net margin performance in 2013.

Pharmaceutical Market Beginning to Show Signs of Stability

According to Global Pharmaceutical Market Benchmark Report, the combined peer group revenue and average operating margin remained stable in 2013 when compared with 2012. Revenue from this peer group came in slightly lower by -0.2% to $718.7 billion. The average operating margin of the peer group was steady at 21.5%; however, this was down by 90 basis points when compared to 2011. On the clinical side, R&D spending grew by $800 million to $111.9 billion in 2013, an increase of 0.7%.

J&J was the growth leader in absolute dollars, increasing by $4.1 billion in 2013, driven by the company's immunology and oncology portfolios. Biogen Idec was the peer group revenue growth leader in 2013. Biogen's sales increased to $5.5 billion in 2013, a 25.7% rise from the $4.2 billion the company reported in 2012. Revenues soared as a result of Tysabri (natalizumab), the company's injectable monotherapy for treating relapsing forms of multiple sclerosis (MS), and the new oral MS drug Tecfidera (dimethyl fumarate). Sales of Tysabri grew 36.4% year to year from $1.1 billion in 2012 to $1.5 billion in 2013. The company also benefited from recognizing $876.1 million in new revenues from sales of Tecfidera despite having only been approved in March of 2013.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Global Pharmaceutical Market Dynamics

  • Sector Overview
  • Corporate Valuations
  • FDA Approved 27 Novel New Drugs in 2013
  • New Approvals Drive Much Needed Value in the Pharmaceutical Market
  • Patent Cliff to Erode $65B in Sales by 2019
  • Orphan Drugs: No Longer a Rare Opportunity
  • Regulatory Notes

4 Collaboration and Acquisition Strategies

  • Deal Values Soar Due to Shire Acquisition
  • Deep Dive: AbbVie Acquires Shire as the Threat of Humira Biosimilars Looms
  • M&A Analysis
  • Licensing and Partnerships

5 Financial Management

  • Global Pharmaceutical Market Competitive Landscape Assessment
  • Financial Management: Heat Map
  • Financial Performance Metrics

6 Expense Management

  • Global Pharmaceutical Market Competitive Landscape Assessment
  • Expense Management: Heat Map
  • Expense Performance Metrics

7 Therapy Franchise Analysis

  • Cardiovascular
  • CNS
  • Diabetes
  • Gastrointestinal
  • Hematology
  • Immunology
  • Infectious Disease
  • Oncology
  • Ophthalmology
  • Respiratory
  • Vaccines

8 Regional Analysis

9 Resource Management Strategies

  • Human Capital Management
  • Drugmakers Expand Manufacturing Capacity for Biologics
  • Firm Utilization: Heat Map
  • Firm Utilization Metrics
  • Capital Management: Heat Map
  • Capital Structure Metrics

10 Future Outlook

  • Global Pharmaceutical Market
  • Company Forecasts

11 Market Data

  • Global Pharmaceutical Market
  • Pipeline Analysis
  • Company Pipeline Profiles
  • Molecule Type

12 Appendix

For more information visit http://www.researchandmarkets.com/research/297z9b/pharmaleaders.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals